Exelixis (EXEL) Earnings Date & Reports

Key Takeaways

• Exelixis reported third-quarter 2026 total revenues of $658.7 million, up 10.2% from $597.8 million a year earlier, exceeding consensus estimates.
• GAAP diluted earnings per share (EPS) reached $0.85, up 23.2% year over year, while non-GAAP diluted EPS came in at $0.94.
• U.S. net product revenues from the cabozantinib franchise climbed to $604.9 million, driven by higher sales volume and a stronger average net selling price.
• Management held full-year 2026 revenue guidance steady at $2.50 billion to $2.55 billion and lowered its effective tax-rate outlook, a potential cushion for future earnings.
• Investor focus now shifts to the zanzalintinib regulatory timeline and upcoming pipeline readouts.
• For more details on this ticker, explore the Major News and Today's Price Move pages, plus dedicated Price Targets and Forecast pages for deeper analysis.
• For automated trade ideas across the market, explore the Trending AI Robots page to see AI-driven strategies in action.

Earnings Context and Why It Matters

Exelixis is an oncology company whose growth has long been anchored to cabozantinib, marketed as CABOMETYX, with a maturing pipeline led by the investigational therapy zanzalintinib. The third-quarter 2026 report matters because it tests whether the flagship franchise can sustain momentum while the company invests toward its next potential growth driver. Coming off a second quarter in which management trimmed full-year revenue guidance due to a slower-than-expected ramp in a key indication, this print offered an important signal on the durability of product demand, expense discipline, and capital allocation. For investors, the results also set expectations ahead of a dense stretch of regulatory and clinical catalysts.

Reported Results

For the third quarter of fiscal 2026, Exelixis reported total revenues of $658.7 million, a 10.2% increase from $597.8 million in the prior-year period and above the consensus estimate of roughly $646.5 million. Net product revenues rose to $604.9 million from $542.9 million, while collaboration revenues edged down to $53.8 million from $54.8 million, reflecting lower milestone-related revenues and development cost reimbursements.

GAAP net income attributable to common shareholders was $218.1 million, up 12.7% year over year, translating to GAAP diluted EPS of $0.85, which topped the consensus estimate of about $0.80. Non-GAAP diluted EPS, which excludes the impact of stock-based compensation, was $0.94, also ahead of expectations. Research and development (R&D) expenses increased to $209.5 million from $199.2 million as the company advanced its clinical programs.

Management reaffirmed full-year 2026 total revenue guidance of $2.50 billion to $2.55 billion and updated its effective tax-rate outlook to 16%–18%, down from a prior range of 21%–23%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening. For investors tracking earnings movers like Exelixis, it offers a practical way to identify opportunities across the broader market.

Market Reaction and Investor Sentiment

Exelixis entered the report with strong momentum, having risen roughly 51% year to date, outperforming the broader market. The fifth consecutive quarter of topping consensus EPS reinforced confidence in the cabozantinib franchise's durability. In after-hours trading following the release, shares held near the $66 level, reflecting a relatively measured initial response as investors weighed the solid beat against the upcoming regulatory decision on zanzalintinib.

Sentiment remains constructive but selectively cautious. Analysts have been adjusting price targets in the weeks ahead of the print, and attention is now concentrated on whether the next phase of growth, centered on zanzalintinib, can materialize on schedule. The unchanged revenue guidance suggests management is balancing near-term execution with disciplined investment in the pipeline.

Forward Outlook and Key Factors to Monitor

The most significant near-term catalyst is the U.S. Food and Drug Administration (FDA) review of zanzalintinib in previously treated metastatic colorectal cancer, with a target action date of March 3, 2027. Current full-year guidance excludes any revenue from a potential approval, meaning a favorable decision would be additive to the top line.

Investors should also watch for topline results from the STELLAR-304 trial in non-clear cell renal cell carcinoma, expected in the first quarter of 2027, as a second pipeline catalyst that could broaden the franchise opportunity.

On the commercial side, the trajectory of CABOMETYX sales volume, net selling price, and gross-to-net deductions will remain key indicators of franchise health. Collaboration and royalty revenues from partners such as Ipsen and Takeda are another variable worth monitoring.

Finally, capital allocation continues to matter. Exelixis repurchased $402.1 million of stock under its current authorization, a practice that supports EPS by reducing the share count while the company funds its R&D priorities and evaluates external innovation opportunities.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations